Secondary sexual dysfunction with antidepressant treatment: Study on 50 patients

2016 ◽  
Vol 33 (S1) ◽  
pp. S591-S591
Author(s):  
O.W. Muquebil Ali Al Shaban Rodriguez ◽  
S. Ocio León ◽  
M. Gómez Simón ◽  
M.J. Hernández González ◽  
E. Álvarez de Morales Gómez-Moreno ◽  
...  
Keyword(s):  
Side Effects ◽  
Sexual Dysfunction ◽  
Treatment Adherence ◽  
Antidepressant Treatment ◽  
Antidepressant Drugs ◽  
Sexual Side Effects ◽  
Competing Interest ◽  
The Relationship ◽  
Transversal Study

IntroductionThe side effects of the various antidepressant drugs on the sexual field (with very few exceptions) are well known, and they affect the quality of life in important manners. The incidence rate, communicated spontaneously by the patient, has been estimated around 10–15%, and can reach amounts of 50–60% with SSRIs when studied specifically. It has been suggested that these effects compromise treatment adherence.ObjectivesTo estimate the incidence and intensity of the side effects on the sexual field with different antidepressants, as well as its relationship with treatment adherence.MethodologyTransversal study on 50 patients assisted in medical consultation. Collection of data in office (October 2014–October 2015).Administration of survey PRSexDQ-SALSEX. In order to research the relationship with treatment adherence, one question surveyed the patient whether he/she had thought about finishing treatment for this reason.ResultsTwenty-nine patients (58% of the sample) presented some degree of sexual dysfunction. Five individuals (17.2%) communicated it spontaneously. Nine individuals (31%) responded that they did not accept positively the changes in their sexual field, and they had thought about withdrawing treatment for this reason. They were given the test of self-compliance statement (Haynes-Sackett), with a result of four non-compliant (44.4%). The most frequently involved drugs were fluoxetine (n = 5, 10% of the sample total) and paroxetine (n = 4, 8%).ConclusionsThe high impact of sexual side effects with a low rate of spontaneous communication coincides with previous existent studies.Limitation when estimating adhesion due to methodological difficulties in the design of the study. However, high impression by using the selected method of determination.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Sexual side effects in patients treated with desvenlafaxine: An observational study in daily practice

2016 ◽  
Vol 33 (S1) ◽  
pp. s227-s228 ◽  
Author(s):  
B. Navarro ◽  
L. Perez ◽  
L. Erkoreka ◽  
A. Arroita ◽  
I. Perez
Keyword(s):  
Side Effects ◽  
Sexual Dysfunction ◽  
Side Effect ◽  
Daily Practice ◽  
Well Being ◽  
Common Side Effect ◽  
Sexual Side Effects ◽  
Health Centres ◽  
Competing Interest ◽  
Orgasmic Dysfunction

IntroductionSexual function is important for patients’ well-being but it is a common side effect of SSRI and SNRI, included desvenlafaxine.Objectives and aimsEvaluate incidence and characteristics of sexual dysfunction caused by desvenlafaxine in the clinical practice.MethodsOne hundred and thirty-three patients with recently introduced desvenlafaxine treatment are recruited from Barakldo and Uribe-Kosta Mental Health Centres in Biscay, Spain. UKU scale is administered to measure sexual side effects. Statistical analysis is performed using SPSS v.22.ResultsSexual dysfunction is observed in 5 patients (3.7%) at 50 and 100 mg/d (2 and 3 patients, respectively) desvenlafaxine doses. Two patients (1.5%) have experimented more than one sexual side effect. Regarding gender differences, the most frequent sexual dysfunctions are diminished sexual desire (5.5%) and erectile dysfunction (5.5%) in men and orgasmic dysfunction (1.2%) in women (P-values are 0.034; 0.034 and 0.408, respectively). Discontinuation is decided in 60% of patients.ConclusionsDesvenlafaxine has a well-tolerated sexual side effect profile in general population. There are some gender-related differences both in presentation and perception, as it has been described with other drugs, and this should be taken into account by prescriptors.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Erectile dysfunction and antipsychotics

2011 ◽  
Vol 26 (S2) ◽  
pp. 1543-1543
Author(s):  
F. Fifani ◽  
Y. Otheman ◽  
M. Outarahout ◽  
A. Ouanass
Keyword(s):  
Quality Of Life ◽  
Erectile Dysfunction ◽  
Side Effects ◽  
Sexual Dysfunction ◽  
Fluphenazine Decanoate ◽  
Antipsychotic Medications ◽  
Sexual Side Effects ◽  
Male Patients ◽  
Classification Evaluation

Sexual side effects associated with antipsychotic medications constitute an understudied set of side effects that diminish a patient's quality of life, and lead to noncompliance with treatment. Male patients frequently report disturbances in erectile and ejaculatory functioning, as well as changes in libido. The capacity to trigger sexual dysfunction differs from one antipsychotic to another. Clinicians prescribing antipsychotic medications should be familiar with the classification, evaluation and treatment of these side effects. The purpose of this study is to assess the occurrence of erectile dysfunction for 5 classes of antipsychotics (Haloperidol, Risperidone, Olanzapine, Amisulpride and Fluphenazine decanoate) in a population of 120 patients, using the International Index of Erectile Dysfunction (IIEF 5).

Intake of Anti-Epileptic Drugs and their Influences on Sexual Dysfunctions

2021 ◽  
Vol 3 (2) ◽  
Author(s):  
Roheela Yasmeen ◽  
Nida Mobeen ◽  
Muhammad Amjad Khan ◽  
Irfan Aslam ◽  
Samia Chaudhry
Keyword(s):  
Quality Of Life ◽  
Sexual Dysfunction ◽  
Neurological Disorders ◽  
Penile Erection ◽  
The Central Nervous System ◽  
Relationship Of ◽  
The Relationship ◽  
The Brain ◽  
Psychiatric Problems

Epilepsy which is also called seizures disorder is an uncontrolled action of the central nervous system. Itis not a single disease but a set of neurological disorders. Actually in this situation, the brain does notreceive a precise signal and as a result an abnormal condition is produced that is usually involuntary inaction. In this review, we aimed to focus on the relationship of anti-epileptic drugs with sexual dysfunctionand adaptation of better remedies that improve a patient’s family life. Sexual dysfunction is a commoncomorbidity in people with epilepsy which badly affects their quality of life. Sexual dysfunction is causedby different factors like psychiatric problems, anti-epileptic drugs (AEDs) and social factors etc. Sexualdysfunctions include ejaculatory failure, lessen libido, penile erection in men and irregular menstrual cyclein women. Common drugs such as Topiramate, Gabapentin (GBP), Valproate (VA), Carbamazepine (CBZ),Olanzapine (OL) and Risperidone (RTG) that are in practice to treat epilepsy usually produced adverseeffect on sexual dysfunction. Even though a lot of studies have been carried out to control sexualdysfunction in epilepsy’s patient, but still research is going on. Medicine such as Cyproheptadine,Mianserin, Buspirone, Yohimbine were found better to treat epilepsy with minimum side effects of sexualdysfunction. Moreover, it is also seen that certain vasodilators, folate , and vitamin supplements areeffective in improving the quality of life.

Insight and aggressive Behavior in acute Schizophrenic Patients

2016 ◽  
Vol 33 (S1) ◽  
pp. S441-S441
Author(s):  
S. Campi ◽  
C. Esposito ◽  
P. andreassi ◽  
P. Bandinelli ◽  
P. Girardi ◽  
...  
Keyword(s):  
Aggressive Behavior ◽  
Treatment Compliance ◽  
Aggressive Behaviors ◽  
Self Monitoring ◽  
Poor Treatment ◽  
Schizophrenic Patients ◽  
Competing Interest ◽  
The Relationship ◽  
Acute Patients

Introductionaggressive behavior in wards is associated to poor treatment compliance and low clinical insight. Most studies focused on the clinical and cognitive dimensions of insight, while the relationship between metacognitive dimension and aggressive behaviors was not investigated. Our aim was to understand what relationship occurs between dimensions of insight (metacognitive, cognitive, clinical), and specific aggressive behaviors in acute patients.Methodswe recruited 75 acute schizophrenic patients using: aQ; MO aS; IS; P aNSS; BCIS.Resultsa positive correlation between the IS score and the hostility, angry and physical aggression sub-scores of the aQ was highlighted, while no correlation between the score of IS and MO aS total score was found. No correlation between the score of the P aNSS G12 item and the aQ scores and MO aS was found, and no correlation between BCIS scores, MO aS and aQ scores was found.Conclusionsin our patients, a higher level of metacognitive insight, but not clinical nor cognitive insight, was associated to higher levels of hostility. we suggest that a higher ability to monitor and appraise one's own altered processes of thought and related discomfort, feeling of destabilization and loss of control, could contribute to enhance resentment and suspiciousness. Findings help develop specific therapeutic strategies to enhance metacognitive and self-monitoring abilities, helping patient's understanding of the illness, improving compliance with treatment, and patient's quality of life. Our results support the multidimensional nature of insight in schizophrenia, confirming that clinical, cognitive and metacognitive dimensions are independent though related facets of the phenomenon of insight in schizophrenia.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Design and Implementation of Antidepressant Decision Making Aids

2012 ◽  
Vol 3 (2) ◽  
Author(s):  
Beth DeJongh ◽  
Robert Haight
Keyword(s):  
Decision Making ◽  
Side Effects ◽  
Sexual Dysfunction ◽  
Antidepressant Treatment ◽  
Decision Aids ◽  
Antidepressant Medication ◽  
Weight Changes ◽  
Patient Centered ◽  
Medication Selection ◽  
Clinical Systems

Objectives: To create easy to understand, antidepressant medication decision making aids and describe the process used to develop the aids for patients diagnosed with depression. Methods: In collaboration with the Institute for Clinical Systems Improvement (ICSI), antidepressant medication decision making aids were developed to enhance patient and physician communication about medication selection. The final versions of the aids were based on design methods created by Dr. Victor M. Montori (Mayo Clinic) and discussions with patients and providers. Five physicians used prototype aids in their outpatient clinics to assess their usefulness. Results: Six prototype antidepressant medication decision making aids were created to review potential side-effects of antidepressant medications. The side effects included were those patients feel are most bothersome or may contribute to premature discontinuation of antidepressant treatment, including: weight changes, sexual dysfunction, sedation, and other unique side effects. The decision aids underwent several revisions before they were distributed to physicians. Physicians reported patients enjoyed using the decision aids and found them useful. The sexual dysfunction card was considered the most useful while the daily administration schedule card was felt to be the least useful. Conclusions: Physicians found the antidepressant decision making aids helpful and felt they improved their usual interactions with patients. The aids may lead to more patient-centered treatment choices and empower patients to become more directly involved in their treatment. Whether the aids improve patient's medication adherence needs to be addressed in future studies.   Type: Student Project

Rosa Damascena Improved Sexual Dysfunction in Males Under Methadone Treatment – Results from a Double-Blind, Randomized, Placebo-Controlled Clinical Trial

2017 ◽  
Vol 41 (S1) ◽  
pp. S281-S281
Author(s):  
V. Farnia ◽  
F. Tatari ◽  
M. Alikhani ◽  
J. Shakeri ◽  
M. Taghizadeh ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Sexual Dysfunction ◽  
Methadone Treatment ◽  
Controlled Clinical Trial ◽  
Rosa Damascena ◽  
Placebo Condition ◽  
Double Blind ◽  
Male Patients ◽  
Competing Interest

IntroductionPatients with severe opioid dependency might be treated with methadone, a pure μ-opioid-receptor, with promising results. Though, as for opioids, side effects are high, and among those, sexual dysfunction is among the most disturbing side effects.AimsInvestigating the influence of Rosa Damascena oil to improve sexual dysfunction among male methadone users.MethodsA total of 60 male patients (mean age: 30 years) with diagnosed opioid dependence and currently under treatment of methadone were randomly assigned either to the verum (Rosa Damascenca oil drops) or placebo condition. At baseline, and four and eight weeks later, patients completed self-rating questionnaires covering sexual dysfunction and happiness.ResultsOver time sexual dysfunction decreased and happiness increased in the verum, but not in the placebo condition.ConclusionsResults from this double blind, randomized, and placebo-controlled clinical trial showed that Rosa Damascena oil improved sexual dysfunction and happiness among male opioid addicts while under substitution treatment with methadone.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Young-onset colorectal cancer treatment side effects: Infertility, sexual dysfunction, and quality-of-life outcomes.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 3587-3587
Author(s):  
Laura Diane Porter ◽  
Ronit Yarden ◽  
Kim Lynn Newcomer ◽  
Negeen Fathi ◽  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Side Effects ◽  
Sexual Dysfunction ◽  
Cancer Patients ◽  
Fertility Preservation ◽  
Cancer Treatments ◽  
Young Onset

3587 Background: Colorectal cancer is the third-most commonly diagnosed cancer and the second-leading cause of cancer death in men and women combined in the United States. Young-onset colorectal cancer refers to individuals diagnosed under the age of 50. In recent years, the incidence has increased by 2.2% annually in individuals younger than 50 years and 1% in individuals 50-64, in contrast to a 3.3% decrease in adults 65 years and older. Young-onset (YO) CRC patients and survivors face unique clinical challenges with fertility and sexual dysfunctions, but this risk is not well quantified. There is limited data and public discussion on the long-term effects of colorectal cancer treatments on fertility and sexual dysfunction and the long-term impact on the quality of life. Methods: To explore the unique challenges and unmet needs of the young-adult patient population, a cross-sectional study was conducted. Colorectal cancer patients and survivors (N = 884) diagnosed between the ages of 20 to 50 years old (median age 42 ± 7.0) completed an online questionnaire based on established instruments EORTC-QOL-30, EORTC-CR-29, and EORTC-SHC-22. Results: Thirty-one percent of respondents stated that a medical professional spoke to them about fertility preservation at the time of diagnosis and during treatment. Only 31% were referred to a reproductive endocrinologist, even though 37% of women and 16% of men reported that treatment left them infertile or sterile. Among survey respondents, 12% of women had an egg retrieval procedure, and 36% of men had their sperm preserved prior to the start of treatment. Fifty-three percent of women reported treatment led to premature menopause. Sixty-five percent of respondents suffer from some level of sexual dysfunction due to treatment. In patients who received radiation therapy, women were 12% less likely than men to have discussed sexual side effects with the provider before treatment. Patients who have an ostomy reported more severe sexual dysfunction (17.8%). Rectal cancer patients were 2.5 times more likely than those with colon cancer to report severe dysfunction after their treatment. More than 25% of the respondents said they would have considered alternative treatment if they would have known the risks of sexual dysfunction. Conclusions: Our survey demonstrates inadequate communications between patients and providers about the irreversible fertility and sexual effects of colorectal cancer treatments. Younger patients and survivors face unique long-term challenges and require further information about fertility preservation options and emotional support regarding their sexuality post-treatment. Other studies are needed to assess the physical and psychological side effects endured by young-onset CRC patients and survivors.

Sexual Dysfunction

2014 ◽  
pp. 97-98
Author(s):  
David L Brody
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Drug Abuse ◽  
Side Effects ◽  
Sexual Dysfunction ◽  
Pde5 Inhibitor ◽  
Cauda Equina ◽  
Sexual Side Effects ◽  
Severe Fatigue ◽  
Cord Injury

This chapter addresses issues surrounding sexual dysfunction after concussion. Ask the patient specifically about sexual dysfunction in private, and if appropriate ask the collateral source separately. Assess for depression, severe fatigue or hypersomnia, untreated pain, and alcohol or drug abuse (especially marijuana). Check medications for sexual side effects; serotonin specific reuptake inhibitors are the most common culprits. Test for hormonal imbalances and unrecognized cauda equina or lower spinal cord injury. Consider a trial of a PDE5 inhibitor and refer to urology for more advanced options.

scholarly journals Antidepressant drugs and sexual dysfunction

2013 ◽  
Vol 202 (6) ◽  
pp. 396-397 ◽  
Author(s):  
David S. Baldwin ◽  
Thomas Foong
Keyword(s):  
Depressive Symptoms ◽  
Sexual Dysfunction ◽  
Sexual Function ◽  
Antidepressant Treatment ◽  
Antidepressant Drugs ◽  
Self Esteem ◽  
Depressive Illness ◽  
Controlled Trials

SummaryDepressive symptoms and depressive illness are associated with impairments in sexual function and satisfaction but the findings of randomised placebo-controlled trials demonstrate that antidepressant drugs can be associated with the development or worsening of sexual dysfunction. Sexual difficulties during antidepressant treatment often resolve as depression lifts but may persist over long periods, and can reduce self-esteem and affect mood and relationships adversely. Sexual dysfunction during antidepressant treatment is typically associated with many possible causes, but the risk of dysfunction varies with differing antidepressants, and should be considered when selecting an antidepressant.

Sign in / Sign up

Export Citation Format

Share Document